Received Feb 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 34MF9 | — |
Inadvertent Use of Kinrix in Children Younger than 4 Years of Age; Kinrix as a 2nd Dtap dose and as 2nd IPV dose; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 4-month-old female patient who received DTPa-IPV (Kinrix) (batch number 34MF9, expiry date 13-FEB-2026) for prophylaxis. Concomitant products included Diphtheria vaccine toxoid, Pertussis vaccine acellular, Tetanus vaccine toxoid (Dtap). On 09-JAN-2025, the patient received Kinrix. On 09-JAN-2025, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Inadvertent Use of Kinrix in Children Younger than 4 Years of Age) and inappropriate schedule of vaccine administered (Verbatim: Kinrix as a 2nd Dtap dose and as 2nd IPV dose). The outcome of the inappropriate age at vaccine administration and inappropriate schedule of vaccine administered were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 24-JAN-2025 The reporter reported 4 months old patient, received Kinrix as a 2nd Dtap dose and as 2nd IPV dose, which led inappropriate age at vaccine administration and inappropriate schedule of vaccine administered. The reporter consented to follow up. This case was linked with case US2025009565 reported by the same reporter, for different patient.; Sender's Comments: US-GSK-US2025009565:Same reporter,Different patient
DTAP